WO2014132060A1 - Skincare compositions - Google Patents
Skincare compositions Download PDFInfo
- Publication number
- WO2014132060A1 WO2014132060A1 PCT/GB2014/050580 GB2014050580W WO2014132060A1 WO 2014132060 A1 WO2014132060 A1 WO 2014132060A1 GB 2014050580 W GB2014050580 W GB 2014050580W WO 2014132060 A1 WO2014132060 A1 WO 2014132060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skincare
- percent
- combination
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Definitions
- This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions.
- Acne vulgaris is a chronic inflammatory condition of the pilosebaceous units of the skin, which is particularly prevalent in adolescents.
- the condition generally causes the formation, on the skin, of comedones, red papules, pustules and sometimes cysts. This is unsightly and furthermore, if untreated, acne can lead to scarring of the skin.
- the major causes of acne are thought to be an increase in sebum production, an increased presence of propionibacterium acne (P. acne), blockage of the pilosebaceus duct and the production of inflammation.
- Salicylic acid is known to be effective in the treatment of acne. It is a topical keratolytic agent that works by dissolving the intercellular cement that holds epithelial cells together. Salicylic acid is used in a variety of over-the-counter acne remedies.
- salicylic acid In order to improve the efficacy of topical acne treatments, it is desired to formulate salicylic acid with one or more control agents to regulate the inflammatory effects sometimes observed, such as local skin peeling and discomfort such as burning and skin reddening.
- compositions (a) and (b) each suitable for topical application to the skin, wherein composition (a) comprises salicylic acid or a salt thereof, combined with at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide and composition (b) comprises at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide.
- this treatment provides advantages over existing acne treatments, particularly in tolerance of the acne treatment by the skin reduction in inflammation in the affected skin and/or a soothing effect. Without wishing to be bound by any theory, it is believed that this treatment may have an effect in reducing the severity of the acne and hence any associated marks or scarring that can occur; furthermore, cutaneous irritation may be reduced.
- Salicylic acid is preferably incorporated into composition (a) according to the invention as the free acid.
- the pH of the composition may, and generally will, be such that the salicylic acid exists in the composition in dissociated form.
- the composition may well contain cationic counterions, the salicylic acid may then be thought of as being present in salt form.
- the salicylic acid may be incorporated into the composition already in salt form, eg as a salt with a Group I metal, such as sodium salicylate.
- any and all references to salicylic acid should be taken to encompass references to the acid and to dissociated forms and salts thereof.
- the concentration of salicylic acid in the composition according to the invention is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
- the concentration of salicylic acid is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
- the concentration of salicylic acid may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
- a particularly preferred concentration of salicylic acid is 2 percent by weight.
- the concentration of niacinamide when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
- the concentration of niacinamide is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
- the concentration of niacinamide may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
- a particularly preferred concentration of niacinamide is 2 percent by weight.
- the concentration of lactic acid or salt thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
- the concentration of lactic acid or a salt or a derivative thereof is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
- the concentration of lactic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
- a particularly preferred concentration of lactic acid or a salt or a derivative thereof is 2 percent by weight.
- the concentration of glycyrrhizinic acid or a salt or a derivative thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight.
- the concentration of glycyrrhizinic acid or a salt or a derivative thereof is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight.
- concentration of glycyrrhizinic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight.
- concentration of glycyrrhizinic acid or a salt or a derivative thereof is 2 percent by weight.
- composition (a) comprises 0.1 to 5 wt% salicylic acid, or a salt thereof, in combination with 0.1 to 5 wt% niacinamide; and composition (b) comprises 0.1 to 5 wt% niacinamide. More preferably composition (a) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide; and composition (b) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide. In a particularly preferred embodiment of the present invention, composition (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide; and composition (b) comprises 2.0wt% niacinamide.
- composition (a) (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid; and composition (b) comprises 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid.
- the composition is preferably prepared with a pH in the range 2.5 to 8.0, more preferably 3.0 to 7.0, and particularly a pH in the range 3.5 to 6.0, e.g. about pH 4.5 or pH 5.5.
- compositions (a) and (b) according to the invention may be formulated in numerous forms. However, the compositions may often take the form of an aqueous or oily solution or surfactant wash or dispersion or emulsion or a gel.
- An emulsion may be an oil-in- water emulsion or a water-in- oil emulsion or microemulsion.
- the oil phase of the emulsion may comprise a) hydrocarbon oils such as paraffin or mineral oils; b) waxes such as beeswax or paraffin wax; c) natural oils such as sunflower oil, apricot kernel oil, shea butter or jojoba oil; d) silicone oils such as dimethicone, cyclomethicone or cetyldimethicone; e) fatty acid esters such as isopropyl palmitate, isopropyl myristate, dioctylmaleate, glyceryl oleate and cetostearyl isononanoate; f) fatty alcohols such as cetyl alcohol or stearyl alcohol and mixtures thereof (eg cetearyl alcohol); g) polypropylene glycol or polyethylene glycol ethers, eg PPG-14 butyl ether; or h) mixtures thereof, for example, the blend of waxes available commercially under the trade name Cutina (Henkel).
- Emulsifiers used may be any emulsifiers known in the art for use in water-in- oil or oil-in-water emulsions or microemulsions.
- Known cosmetically acceptable emulsifiers may include: a) sesquioleates such as sorbitan sesquioleate, available commercially for example under the trade name Arlacel 83 (ICI), or polyglyceryl-2- sesquioleate; b) ethoxylated esters of derivatives of natural oils such as the polyethoxylated ester of hydrogenated castor oil available commercially for example under the trade name Arlacel 989 (ICI); c) silicone emulsifiers such as silicone polyols available commercially for example under the trade name ABIL WS08 (Th.
- emulsifiers such as fatty acid soaps e.g. potassium stearate and fatty acid sulphates e.g. sodium cetostearyl sulphate available commercially under the trade name Dehydag (Henkel); e) ethoxylated fatty alcohols, for example the emulsifiers available commercially under the trade name Brij (ICI); f) sorbitan esters, for example the emulsifiers available commercially under the trade name Span (ICI); g) ethoxylated sorbitan esters, for example the emulsifiers available commercially under the trade name Tween (ICI); h) ethoxylated fatty acid esters such as ethoxylated stearates, glyceryl monostearates for example the emulsifiers available commercially under the trade name Myrj (ICI); i) ethoxylated mono-, di-, and
- Gels provided according to the invention may be aqueous or non-aqueous. Aqueous gels are preferred.
- the gel will contain a gelling agents in order to give sufficient viscosity to the gel.
- the gel may further comprise thickening agents.
- Suitable gelling agents may be hydroxypropyl guar or a copolymer of acryloyl dimethyl tauric acid (or a salt thereof), especially a copolymer of that monomer with another vinylic monomer.
- the salt may be a salt of a Group I alkali metal, but is more preferably an ammonium salt.
- suitable copolymer gelling agents are ammonium acryloyl dimethyl taurate / vinyl pyrrolidone copolymer, ammonium acryloyl dimethyl taurate / Beheneth-25 methacrylate copolymer, ammonium acryloyldimethyltaurate / vinyl formamide copolymer These materials are available from Clariant GmbH in the range of products under the trade name Aristoflex.
- thickening agents may also be used according to the nature of the liquid carrier and the viscosity required.
- Thickeners that are water-soluble or hydrophilic are preferred, and examples include acrylic acid polymers, eg those available commercially under the trade name Carbopol (B.F. Goodrich), modified celluloses, eg hydroxypropylmethylcellulose or hydroxyethylcellulose available commercially under the trade name Natrosol (Hercules), alkylgalactomanans available under the trade name N-Hance, xanthan gum, cetyl alcohol and sodium chloride.
- the amount of gelling and/or thickening agent in the composition will each preferably lie in the range 0.1 to 5 percent w/w, more preferably 0.5 to 5 percent w/w. Typically, the amount of gelling and/or thickening agent will each be less than 3 percent w/w, eg about 1 percent w/w or about 2 percent w/w.
- the composition according to the invention preferably has a viscosity of from about 10,000 mPa.s to about 200,000 mPa.s, Viscosity may be measured using a Brookfield RVT viscometer equipped with a T bar C rotating at 5rpm for 1 minute.
- the composition should comprise a chelating or sequestering agent, or other agent capable of complexation or other interaction with metal ions present in the composition.
- chelating or sequestering agents include ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium salt.
- the composition will generally contain a solvent system or other continuous liquid phase. Such a system is preferably aqueous.
- mixed solvent systems may often be used with advantage.
- Such a mixed solvent system most preferably comprises water, in admixture with a co-solvent, most preferably a lower (eg Ci-6) alcohol, in particular ethanol and t-butyl alcohol.
- Preferred aqueous systems comprise water in an amount of at least 25 percent by weight, more preferably at least 35 percent by weight, The upper limit of water will depend on the amounts of other ingredients incorporated in the composition so that the water may form the remainder of the composition up to 100 percent of the composition.
- composition may additionally comprise other components which will be well known to those skilled in the art.
- these include, for example: a) Emollients - ingredients that help to maintain the soft, smooth and pliable appearance of skin.
- Such ingredients may function by their ability to remain on the surface of the skin or in the stratum corneum, and to act as lubricants, reducing or preventing flaking of the skin and improving the skin's appearance.
- emollients are isopropyl myristate, triglycerides of fatty acids eg lauric triglyceride or capric/caprylic triglyceride, such as the triglyceride available commercially under the trade name Miglyol 810 (Huls UK), and the polypropylene glycol ether of stearyl alcohol known as PPF-15 Stearyl Ether.
- Particularly preferred emollients are octyldodecanol and polysiloxane compounds, in particular those known as dimethicones.
- surfactants may be used in compositions according to the invention as solubilisers, or as cleansing agents or foam boosters. Many different classes of surfactant may be suitable for inclusion in the composition according to the invention, and these will be readily apparent to those skilled in the art. Examples of suitable surfactants include anionic surfactants (eg sodium laureth sulphate , non ionic surfactants (eg cocoglucoside) cationic surfactants and/or amphoteric surfactants (eg cocoamidoproyl betaine).
- anionic surfactants eg sodium laureth sulphate
- non ionic surfactants eg cocoglucoside
- amphoteric surfactants eg cocoamidoproyl betaine
- Polyethylene glycol ethers of alcohols such as isocetyl alcohol (eg Isoceteth- 20), isostearyl alcohol (eg lsosteareth-20), cetyl alcohol (eg Ceteth- 20), oleyl alcohol (eg Oleth-20) and cetearyl alcohol (eg Ceteareth-20).
- Preservatives - ingredients which prevent or retard microbial growth and thus protect the composition from spoilage. Examples of preservatives include such as propylparaben, bronopol, sodium dehydroacetate, polyhexamethylenebiguanide hydrochloride, isothiazolone and diazolidinylurea.
- Chelating agents or sequestering agents (sequestrants) - ingredients that have the ability to complex with and inactivate metallic ions in order to prevent their adverse effects on the stability or appearance of the composition, as described above.
- chelating agents are ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium or tetrasodium salt.
- pH adjusters Ingredients used to control the pH of the composition.
- pH adjusters are inorganic salts such as sodium hydroxide, and organic bases such as triethanolamine and arginine.
- Conditioning agents for example distearyldimonium chloride.
- Perfumes and colourings are examples of pH adjusters.
- composition according to the invention may be applied and left on the skin to have the desired therapeutic effect or it may be applied and then rinsed off, for example with water for surfactant based formulations.
- the composition may be applied with the aid of a fibrous material, for example a pad or a wipe.
- an article comprising a fibrous substrate, for example a material in the form of a pad or a wipe, impregnated with a first skincare composition, composition (a), and a second skincare composition, composition (b), as described in the first aspect of the present invention.
- a fibrous substrate for example a material in the form of a pad or a wipe
- the first composition may be applied to one side of the wipe and the second composition may be applied to the second side of the wipe.
- the first composition may be applied to one end of the wipe and the second composition may be applied to the opposite end of the wipe.
- Suitable fibrous materials include cellulose or cotton fibres or a mixture thereof.
- the fibrous material may be impregnated with the composition as a wet wipe which is arranged for immediate use to apply the skincare composition of the present invention to the skin of the user.
- the fibrous material may be impregnated with the skincare composition and dried to form a dry wipe which requires to be wetted, for example with water, before it can be used.
- method for the prophylactic or remedial treatment of acne comprises the topical application to the skin of a first skincare composition and a second skincare composition as described in the first aspect of the present invention.
- the method according to this aspect of the invention may be a therapeutic method, but will often be a primarily cosmetic method, the objective of which is to reduce or eliminate externally visible, and often unsightly, symptoms of acne vulgaris.
- the method further comprises at least one additional step of topically applying the second composition.
- the second composition is preferably applied up to three additional times. In one preferred embodiment the second composition is applied one additional time (two times overall). In an alternative preferred embodiment the second composition is applied two additional times (three times overall).
- a combination of a first skincare composition and a second skincare composition as described in the first aspect of the present invention in the manufacture of a kit for the prophylactic or remedial treatment of acne by topical application of both the first and second compositions to the skin.
- the term 'derivative' as used herein is intended to cover compounds that are suitable for use in skincare compositions such as esters.
- formulations of the present application can be prepared using standard methods known to the man skilled in the art.
- Formulation (a) is applied to the skin and allowed to dry followed by formulation (b).
- Formulation (b) can be re-applied several times before a repeat of formulation (a) is required.
- in vitro testing was to evaluate the potential antiinflammatory action of compositions according to the present invention.
- In vitro tests were carried out as follows: • take an irritant treated EpiDerm (TM) skin model. Initial inflammation was measured by the cytokine release after exposure to a single dose of irritant.
- TM EpiDerm
- a salicylic acid/niacinamide combination achieves an anti-inflammatory effect, but that further treatment with a niacinamide-containing formulation according to the invention significantly enhances the inflammatory behaviour of each of these ingredients - by repeating the application of the niacinamide on the top of the salicylic acid during the following hours helps to continue boosting the antiinflammatory effect.
- This synergistic behaviour is totally unexpected and permits the formulation of products according to the invention such as the one tested which have a broad range of active ingredients to deal with traumas arising from every stage in the lifecycle of a specific acne event or related skin inflammation. Further modifications and developments can be made without departing from the scope of the invention described herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to a skincare combination comprising at least 2 separate compositions (a) and (b) each suitable for topical application to the skin, wherein composition (a) comprises salicylic acid or a salt thereof, combined with at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide and composition (b) comprises at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide.
Description
SKI NCARE COMPOSITIONS
This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions.
Acne vulgaris (acne) is a chronic inflammatory condition of the pilosebaceous units of the skin, which is particularly prevalent in adolescents. The condition generally causes the formation, on the skin, of comedones, red papules, pustules and sometimes cysts. This is unsightly and furthermore, if untreated, acne can lead to scarring of the skin. The major causes of acne are thought to be an increase in sebum production, an increased presence of propionibacterium acne (P. acne), blockage of the pilosebaceus duct and the production of inflammation.
Salicylic acid is known to be effective in the treatment of acne. It is a topical keratolytic agent that works by dissolving the intercellular cement that holds epithelial cells together. Salicylic acid is used in a variety of over-the-counter acne remedies.
In order to improve the efficacy of topical acne treatments, it is desired to formulate salicylic acid with one or more control agents to regulate the inflammatory effects sometimes observed, such as local skin peeling and discomfort such as burning and skin reddening.
It is known that the application of skincare compositions comprising salicylic acid and additional actives can result in an improved therapeutic efficacy in the treatment of acne. Said skincare compositions have both the ability to treat acne and reduce the appearance of redness on the skin.
It has now been unexpectedly found that the efficacy of the salicylic acid in such formulations can be increased by the application of a second formulation which does not include salicylic acid.
Thus, according to a first aspect of the invention there is provided a skincare combination comprising at least 2 separate compositions (a) and (b) each suitable for topical application to the skin, wherein composition (a) comprises salicylic acid or a salt thereof, combined with at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide and composition (b) comprises at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide. It has been found that this treatment provides advantages over existing acne treatments, particularly in tolerance of the acne treatment by the skin reduction in inflammation in the affected skin and/or a soothing effect. Without wishing to be bound by any theory, it is believed that this treatment may have an effect in reducing the severity of the acne and hence any associated marks or scarring that can occur; furthermore, cutaneous irritation may be reduced.
Salicylic acid is preferably incorporated into composition (a) according to the invention as the free acid. However, the pH of the composition may, and generally will, be such that the salicylic acid exists in the composition in dissociated form. As the composition may well contain cationic counterions, the salicylic acid may then be thought of as being present in salt form. Alternatively, the salicylic acid may be incorporated into the composition already in salt form, eg as a salt with a Group I metal, such as sodium salicylate. As used herein, unless the context requires otherwise, any and all references to salicylic acid should be taken to encompass references to the acid and to dissociated forms and salts thereof.
The concentration of salicylic acid in the composition according to the invention is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight. The concentration of salicylic acid is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight. The concentration of
salicylic acid may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight. A particularly preferred concentration of salicylic acid is 2 percent by weight.
The concentration of niacinamide when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight. The concentration of niacinamide is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight. The concentration of niacinamide may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight. A particularly preferred concentration of niacinamide is 2 percent by weight.
The concentration of lactic acid or salt thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight. The concentration of lactic acid or a salt or a derivative thereof is preferably less than 10 percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight. The concentration of lactic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight. A particularly preferred concentration of lactic acid or a salt or a derivative thereof is 2 percent by weight. The concentration of glycyrrhizinic acid or a salt or a derivative thereof when present in either composition (a) or (b) is preferably at least 0.01 percent by weight, more preferably at least 0.1 percent, most preferably at least 0.5 percent and especially at least 1 percent by weight. The concentration of glycyrrhizinic acid or a salt or a derivative thereof is preferably less than 10
percent, more preferably less than 5 percent, most preferably less than 4 percent and especially less than 3 percent by weight. The concentration of glycyrrhizinic acid or a salt or a derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight, more preferably 0.1 percent to 5 percent, and most preferably 0.5 percent to 4 percent and especially 1 to 3 percent by weight. A particularly preferred concentration of glycyrrhizinic acid or a salt or a derivative thereof is 2 percent by weight.
Preferably composition (a) comprises 0.1 to 5 wt% salicylic acid, or a salt thereof, in combination with 0.1 to 5 wt% niacinamide; and composition (b) comprises 0.1 to 5 wt% niacinamide. More preferably composition (a) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide; and composition (b) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide. In a particularly preferred embodiment of the present invention, composition (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide; and composition (b) comprises 2.0wt% niacinamide.
In an alternative preferred embodiment, composition (a) (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid; and composition (b) comprises 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid. The composition is preferably prepared with a pH in the range 2.5 to 8.0, more preferably 3.0 to 7.0, and particularly a pH in the range 3.5 to 6.0, e.g. about pH 4.5 or pH 5.5.
Each of compositions (a) and (b) according to the invention may be formulated in numerous forms. However, the compositions may often take the form of an aqueous or oily solution or surfactant wash or dispersion or emulsion or a gel. An emulsion may be an oil-in- water emulsion or a water-in- oil emulsion or microemulsion.
The oil phase of the emulsion may comprise a) hydrocarbon oils such as paraffin or mineral oils; b) waxes such as beeswax or paraffin wax; c) natural oils such as sunflower oil, apricot kernel oil, shea butter or jojoba oil; d) silicone oils such as dimethicone, cyclomethicone or cetyldimethicone; e) fatty acid esters such as isopropyl palmitate, isopropyl myristate, dioctylmaleate, glyceryl oleate and cetostearyl isononanoate; f) fatty alcohols such as cetyl alcohol or stearyl alcohol and mixtures thereof (eg cetearyl alcohol); g) polypropylene glycol or polyethylene glycol ethers, eg PPG-14 butyl ether; or h) mixtures thereof, for example, the blend of waxes available commercially under the trade name Cutina (Henkel).
Emulsifiers used may be any emulsifiers known in the art for use in water-in- oil or oil-in-water emulsions or microemulsions. Known cosmetically acceptable emulsifiers may include: a) sesquioleates such as sorbitan sesquioleate, available commercially for example under the trade name Arlacel 83 (ICI), or polyglyceryl-2- sesquioleate; b) ethoxylated esters of derivatives of natural oils such as the polyethoxylated ester of hydrogenated castor oil available commercially for example under the trade name Arlacel 989 (ICI); c) silicone emulsifiers such as silicone polyols available commercially for example under the trade name ABIL WS08 (Th. Goldschmidt AG); d) anionic emulsifiers such as fatty acid soaps e.g. potassium stearate and fatty acid sulphates e.g. sodium cetostearyl sulphate available commercially under the trade name Dehydag (Henkel); e) ethoxylated fatty alcohols, for example the emulsifiers available commercially under the trade name Brij (ICI); f) sorbitan esters, for example the emulsifiers available commercially under the trade name Span (ICI); g) ethoxylated sorbitan esters, for example the emulsifiers available commercially under the trade name Tween (ICI); h) ethoxylated fatty acid esters such as ethoxylated stearates, glyceryl monostearates for example the emulsifiers available commercially under the trade name Myrj (ICI); i) ethoxylated mono-, di-, and tri-glycerides, for example the emulsifiers available commercially under the trade name Labrafil (Alfa Chem.); j) non-ionic self-emulsifying waxes, for example the wax available commercially under the trade name Polawax (Croda); k) ethoxylated fatty acids, for example, the emulsifiers available commercially under the
trade name Tefose (Alfa Chem.) I) methylglucose esters such as polyglycerol- 3 methyl glucose distearate available commercially under the name Tegocare 450 (Degussa Goldschmidt);. m) as well as polyacrylamide emulsifier systems for examples cream gel emulsifier under trade name Sepigel 305 ( Seppic) or n) mixtures thereof
Gels provided according to the invention may be aqueous or non-aqueous. Aqueous gels are preferred. The gel will contain a gelling agents in order to give sufficient viscosity to the gel. The gel may further comprise thickening agents.
Suitable gelling agents may be hydroxypropyl guar or a copolymer of acryloyl dimethyl tauric acid (or a salt thereof), especially a copolymer of that monomer with another vinylic monomer. The salt may be a salt of a Group I alkali metal, but is more preferably an ammonium salt. Examples of suitable copolymer gelling agents are ammonium acryloyl dimethyl taurate / vinyl pyrrolidone copolymer, ammonium acryloyl dimethyl taurate / Beheneth-25 methacrylate copolymer, ammonium acryloyldimethyltaurate / vinyl formamide copolymer These materials are available from Clariant GmbH in the range of products under the trade name Aristoflex.
A variety of thickening agents may also be used according to the nature of the liquid carrier and the viscosity required. Thickeners that are water-soluble or hydrophilic are preferred, and examples include acrylic acid polymers, eg those available commercially under the trade name Carbopol (B.F. Goodrich), modified celluloses, eg hydroxypropylmethylcellulose or hydroxyethylcellulose available commercially under the trade name Natrosol (Hercules), alkylgalactomanans available under the trade name N-Hance, xanthan gum, cetyl alcohol and sodium chloride.
The amount of gelling and/or thickening agent in the composition will each preferably lie in the range 0.1 to 5 percent w/w, more preferably 0.5 to 5 percent w/w. Typically, the amount of gelling and/or thickening agent will each be less than 3 percent w/w, eg about 1 percent w/w or about 2 percent w/w.
The composition according to the invention preferably has a viscosity of from about 10,000 mPa.s to about 200,000 mPa.s, Viscosity may be measured using a Brookfield RVT viscometer equipped with a T bar C rotating at 5rpm for 1 minute.
In many instances, it is preferred that the composition should comprise a chelating or sequestering agent, or other agent capable of complexation or other interaction with metal ions present in the composition. Such agents may improve the stability of the composition, and in particular may inhibit or prevent degradation of several ingredients (eg fragrance). Examples of chelating or sequestering agents include ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium salt. In the case of solutions or dispersions, and gels, the composition will generally contain a solvent system or other continuous liquid phase. Such a system is preferably aqueous. However, mixed solvent systems may often be used with advantage. Such a mixed solvent system most preferably comprises water, in admixture with a co-solvent, most preferably a lower (eg Ci-6) alcohol, in particular ethanol and t-butyl alcohol.
Preferred aqueous systems comprise water in an amount of at least 25 percent by weight, more preferably at least 35 percent by weight, The upper limit of water will depend on the amounts of other ingredients incorporated in the composition so that the water may form the remainder of the composition up to 100 percent of the composition.
The composition may additionally comprise other components which will be well known to those skilled in the art. These include, for example: a) Emollients - ingredients that help to maintain the soft, smooth and pliable appearance of skin. Such ingredients may function by their ability to remain on the surface of the skin or in the stratum corneum, and to act as lubricants, reducing or preventing flaking of the skin and improving the skin's
appearance. Examples of emollients are isopropyl myristate, triglycerides of fatty acids eg lauric triglyceride or capric/caprylic triglyceride, such as the triglyceride available commercially under the trade name Miglyol 810 (Huls UK), and the polypropylene glycol ether of stearyl alcohol known as PPF-15 Stearyl Ether. Particularly preferred emollients are octyldodecanol and polysiloxane compounds, in particular those known as dimethicones. b) Humectants or Moisturisers - ingredients intended to increase the water content of the top layers of the skin. Examples of such ingredients are glycerin, sorbitol, 1 ,3-butylene glycol and propylene glycol. c) Surfactants - Surfactants may be used in compositions according to the invention as solubilisers, or as cleansing agents or foam boosters. Many different classes of surfactant may be suitable for inclusion in the composition according to the invention, and these will be readily apparent to those skilled in the art. Examples of suitable surfactants include anionic surfactants ( eg sodium laureth sulphate , non ionic surfactants (eg cocoglucoside) cationic surfactants and/or amphoteric surfactants (eg cocoamidoproyl betaine). Polyethylene glycol ethers of alcohols such as isocetyl alcohol (eg Isoceteth- 20), isostearyl alcohol (eg lsosteareth-20), cetyl alcohol (eg Ceteth- 20), oleyl alcohol (eg Oleth-20) and cetearyl alcohol (eg Ceteareth-20). d) Preservatives - ingredients which prevent or retard microbial growth and thus protect the composition from spoilage. Examples of preservatives include such as propylparaben, bronopol, sodium dehydroacetate, polyhexamethylenebiguanide hydrochloride, isothiazolone and diazolidinylurea. e) Chelating agents or sequestering agents (sequestrants) - ingredients that have the ability to complex with and inactivate metallic ions in order to prevent their adverse effects on the stability or appearance of the composition, as described above. Examples of chelating agents are ethylenediamine tetraacetic acid and its salts, notably the dipotassium and especially the disodium or tetrasodium salt.
f) Abrasives - ingredients used to assist in the removal of unwanted tissue or foreign materials from the skin during application of the composition. Abrasives commonly comprise fine solid particles. Examples of suitable abrasives are polyethylene beads and aluminium oxide g) opacifying agents such as clays ( eg kaolin and bentonite) as well as titanium dioxide. h) pH adjusters - Ingredients used to control the pH of the composition. Examples of pH adjusters are inorganic salts such as sodium hydroxide, and organic bases such as triethanolamine and arginine. i) Conditioning agents, for example distearyldimonium chloride. j) Perfumes and colourings.
The composition according to the invention may be applied and left on the skin to have the desired therapeutic effect or it may be applied and then rinsed off, for example with water for surfactant based formulations. The composition may be applied with the aid of a fibrous material, for example a pad or a wipe.
According to another aspect of the invention, there is provided an article comprising a fibrous substrate, for example a material in the form of a pad or a wipe, impregnated with a first skincare composition, composition (a), and a second skincare composition, composition (b), as described in the first aspect of the present invention. For example, if the fibrous material is a wipe then the first composition may be applied to one side of the wipe and the second composition may be applied to the second side of the wipe. Alternatively, the first composition may be applied to one end of the wipe and the second composition may be applied to the opposite end of the wipe.
Suitable fibrous materials include cellulose or cotton fibres or a mixture thereof. The fibrous material may be impregnated with the composition as a wet wipe which is arranged for immediate use to apply the skincare composition of the present invention to the skin of the user. Alternatively, the fibrous material may be impregnated with the skincare composition and dried to form a dry wipe which requires to be wetted, for example with water, before it can be used. According to a further aspect of the invention, there is provided method for the prophylactic or remedial treatment of acne, which method comprises the topical application to the skin of a first skincare composition and a second skincare composition as described in the first aspect of the present invention. It will be appreciated that the method according to this aspect of the invention may be a therapeutic method, but will often be a primarily cosmetic method, the objective of which is to reduce or eliminate externally visible, and often unsightly, symptoms of acne vulgaris. Optionally the method further comprises at least one additional step of topically applying the second composition.
The second composition is preferably applied up to three additional times. In one preferred embodiment the second composition is applied one additional time (two times overall). In an alternative preferred embodiment the second composition is applied two additional times (three times overall).
In a yet further aspect of the invention, there is provided the use of a combination of a first skincare composition and a second skincare composition as described in the first aspect of the present invention in the manufacture of a kit for the prophylactic or remedial treatment of acne by topical application of both the first and second compositions to the skin.
The term 'derivative' as used herein is intended to cover compounds that are suitable for use in skincare compositions such as esters.
The invention will now be described in greater detail, by way of illustration only, with reference to the following Example.
Example
Formulation (a)
Component Function % w/w in Formula
Deionised Water Water 70.48
Colorona Magestic Green Colour 0.8
SunCROMA Chromium Oxide Green Colour 0.84
DRY FLO PC Starch Humectant 5.2
High Purity Grade Titanium Dioxide Colour 3.43
Keltrol CG RD Rheology modifier 0.3
Veegum Ultra Rheology modifier 0.3
Propylene Glycol Humectant 3
Steareth-2 Emulsifier 2.5
Steareth-21 Emulsifier 1 .5
Eutanol G Emollient 4
Cetiol CC Emollient 2
Sepigel 305 Stabilizing agent 1 .6
Fragrance Fragrance 0.1
Cetearyl Alcohol Emulsifier 0.6
Niacinamide Soothing agent 2
Euxyl K 220 preservative 0.1
Euxyl PE 9010 preservative 0.35
Edenor C18-98 MY emulsifier 0.9
Formulation (b)
The formulations of the present application can be prepared using standard methods known to the man skilled in the art.
Formulation (a) is applied to the skin and allowed to dry followed by formulation (b). Formulation (b) can be re-applied several times before a repeat of formulation (a) is required.
The purpose of the in vitro testing was to evaluate the potential antiinflammatory action of compositions according to the present invention. In vitro tests were carried out as follows:
• take an irritant treated EpiDerm (TM) skin model. Initial inflammation was measured by the cytokine release after exposure to a single dose of irritant.
• apply test compositions to the irritant treated EpiDerm skin
· anti-inflammatory potential was then measured by reduction in cytokine release
• specifically, the levels of cytokines TNF-a, I L-6 and IL-8 were measured to give a picture of the performance of the product across the lifecycle of an acne event or related skin inflammation.
Experimental design follows standard procedures, using phorbol-12-myristate 13-acetate (PMA) as irritant.
A salicylic acid/niacinamide combination achieves an anti-inflammatory effect, but that further treatment with a niacinamide-containing formulation according to the invention significantly enhances the inflammatory behaviour of each of these ingredients - by repeating the application of the niacinamide on the top of the salicylic acid during the following hours helps to continue boosting the antiinflammatory effect. This synergistic behaviour is totally unexpected and permits the formulation of products according to the invention such as the one tested which have a broad range of active ingredients to deal with traumas arising from every stage in the lifecycle of a specific acne event or related skin inflammation. Further modifications and developments can be made without departing from the scope of the invention described herein.
Claims
Claims:
A skincare combination comprising at least 2 separate compositions (a) and (b) each suitable for topical application to the skin, wherein composition (a) comprises salicylic acid or a salt thereof, combined with at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide and composition (b) comprises at least 1 active selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; and niacinamide.
A skincare combination as claimed in Claim 1 wherein the concentration of salicylic acid is in the range 0.01 percent to 10 percent by weight.
A skincare combination as claimed in Claim 2 wherein the concentration of salicylic acid is 1 to 3 percent by weight.
A skincare combination as claimed in Claim 3 wherein the concentration of salicylic acid is 2 percent by weight.
A skincare combination as claimed in any of the preceding Claims wherein the concentration of niacinamide when present in either composition (a) or (b) is 0.01 percent to 10 by weight.
A skincare combination as claimed in Claim 5 wherein the concentration of niacinamide is 1 to 3 percent by weight.
A skincare combination as claimed in Claim 6 wherein the concentration of niacinamide is 2 percent by weight.
A skincare combination as claimed in any of Claims 1 - 4 wherein the concentration of lactic acid or salt thereof when present in either composition (a) or (b) is concentration of lactic acid or a salt or a
derivative thereof may therefore fall in the range 0.01 percent to 10 percent by weight
9. A skincare combination as claimed in Claim 8 wherein the concentration of lactic acid or salt is 1 to 3 percent by weight.
10. A skincare combination as claimed Claim 9 wherein the concentration of lactic acid or salt is 2 percent by weight.
1 1 . A skincare combination as claimed in any of Claims 1 - 4 wherein the concentration of glycyrrhizinic acid or a salt or a derivative thereof when present in either composition (a) or (b) is in the range 0.01 percent to 10 percent by weight.
12. A skincare combination as claimed in Claim 1 1 wherein the concentration of glycyrrhizinic acid or a salt or a derivative thereof is 1 to 3 percent by weight.
13. A skincare combination as claimed in Claim 12 wherein the concentration of glycyrrhizinic acid or a salt or a derivative thereof is 2 percent by weight.
14. A skincare combination as claimed in any of Claims 1 - 7 wherein composition (a) comprises 0.1 to 5 wt% salicylic acid, or a salt thereof, in combination with 0.1 to 5 wt% niacinamide; and composition (b) comprises 0.1 to 5 wt% niacinamide.
15. A skincare combination as claimed in Claim 14 wherein composition (a) comprises 1 to 3 wt% salicylic acid or a salt thereof; in combination 1 to 3 wt% niacinamide; and composition (b) comprises 1 to 3 wt% niacinamide.
16. A skincare combination as claimed in Claim 15 wherein composition (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with
2.0wt% niacinamide; and composition (b) comprises 2.0wt% niacinamide.
17. A skincare combination as claimed in Claim 1 wherein composition (a) comprises 2.0wt% salicylic acid, or a salt thereof, in combination with
2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid; and composition (b) comprises 2.0wt% niacinamide, 2.0wt% lactic acid and 0.05% glycyrrhizinic acid. 18. A skincare combination as claimed in any of the preceding Claims wherein either of composition (a) or composition (b) is prepared with a pH in the range 2.5 to 8.0.
19. A skincare combination as claimed in any of the preceding Claims wherein either of composition (a) or composition (b) is in the form of an aqueous or oily solution or surfactant wash or dispersion or emulsion or a gel.
20. An article comprising a fibrous substrate in the form of a pad or a wipe, impregnated with a first skincare composition, composition (a) and a second skincare composition, composition (b) as claimed in any of the preceding Claims.
21 . An article as claimed in Claim 20 wherein the first skincare composition, composition (a), is applied to one side of said article and the second skincare composition, composition (b), is applied to the second side of the article.
22. An article as claimed in Claim 20 wherein the first skincare composition, composition (a), is applied to one end of said article and the second skincare composition, composition (b), is applied to the opposite end side of the article.
23. A method for the prophylactic or remedial treatment of acne, which method comprises the topical application to the skin of a combination comprising a first skincare composition, composition (a), and a second skincare composition, composition (b) as claimed in any of Claims 1 - 19.
24. A method as claimed in Claim 23 wherein the method further comprises at least one additional step of topically applying the second skincare composition, composition (b).
25. The use of a combination of as claimed in any of Claims 1 - 19 in the manufacture of a kit for the prophylactic or remedial treatment of acne by topical application of both the first and second compositions to the skin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1303640.5A GB2511350B (en) | 2013-03-01 | 2013-03-01 | Skincare compositions |
| GB1303640.5 | 2013-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014132060A1 true WO2014132060A1 (en) | 2014-09-04 |
Family
ID=48142219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2014/050580 Ceased WO2014132060A1 (en) | 2013-03-01 | 2014-02-27 | Skincare compositions |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2511350B (en) |
| WO (1) | WO2014132060A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214532A (en) * | 2016-07-26 | 2016-12-14 | 广州智媛生物科技有限公司 | There is compositions of control oil bacteriostasis efficacy and preparation method thereof |
| US10874600B2 (en) | 2018-06-18 | 2020-12-29 | The Procter & Gamble Company | Method for degrading bilirubin in skin |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| US12440530B2 (en) | 2013-03-01 | 2025-10-14 | Envy Medical, Inc. | Skin solution with solubilized bakuchiol |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015127390A1 (en) | 2014-02-21 | 2015-08-27 | Avadim Technologies, Inc. | Method for maintenance of urethral catheters |
| CA2968525A1 (en) | 2014-11-19 | 2016-05-26 | Avadim Technologies, Inc. | Method for the prevention and treatment of acne |
| EP3982909A4 (en) | 2019-06-12 | 2023-11-29 | Avadim Health, Inc. | COMPOSITIONS AND METHODS FOR THE ANTISEPTIC TREATMENT OF BIOFILM ON MAMMAL TISSUE |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003779A1 (en) * | 1993-07-30 | 1995-02-09 | Unilever Plc | Cosmetic composition containing hydroxyacids |
| WO1996027365A1 (en) * | 1995-03-03 | 1996-09-12 | Avon Products, Inc. | Gentle anti-acne composition |
| WO2000002593A2 (en) * | 1998-07-09 | 2000-01-20 | Transphyto S.A. | Cleansing and treating lotion for treating comedones |
| US20030027738A1 (en) * | 2001-06-22 | 2003-02-06 | L'oreal | Cosmetic and dermatological article |
| US20040081672A1 (en) * | 2002-10-25 | 2004-04-29 | Gupta Shyam K. | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging |
| DE10338615A1 (en) * | 2003-08-22 | 2005-03-17 | Beiersdorf Ag | Cosmetic or dermatological composition comprising lactic acid and ground pumice, e.g. useful as a skin cleansing mask or for treating unclean skin and/or acne, has a defined pH |
| WO2011007183A2 (en) * | 2009-07-17 | 2011-01-20 | Reckitt Benckiser Healthcare International Limited | Skincare compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189406B1 (en) * | 1999-06-23 | 2007-03-13 | Dennis Gross | Composition and method for treating skin |
| FR2980691B1 (en) * | 2011-09-30 | 2014-03-14 | Galderma Sa | WASHING COMPOSITION |
-
2013
- 2013-03-01 GB GB1303640.5A patent/GB2511350B/en not_active Expired - Fee Related
-
2014
- 2014-02-27 WO PCT/GB2014/050580 patent/WO2014132060A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003779A1 (en) * | 1993-07-30 | 1995-02-09 | Unilever Plc | Cosmetic composition containing hydroxyacids |
| WO1996027365A1 (en) * | 1995-03-03 | 1996-09-12 | Avon Products, Inc. | Gentle anti-acne composition |
| WO2000002593A2 (en) * | 1998-07-09 | 2000-01-20 | Transphyto S.A. | Cleansing and treating lotion for treating comedones |
| US20030027738A1 (en) * | 2001-06-22 | 2003-02-06 | L'oreal | Cosmetic and dermatological article |
| US20040081672A1 (en) * | 2002-10-25 | 2004-04-29 | Gupta Shyam K. | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging |
| DE10338615A1 (en) * | 2003-08-22 | 2005-03-17 | Beiersdorf Ag | Cosmetic or dermatological composition comprising lactic acid and ground pumice, e.g. useful as a skin cleansing mask or for treating unclean skin and/or acne, has a defined pH |
| WO2011007183A2 (en) * | 2009-07-17 | 2011-01-20 | Reckitt Benckiser Healthcare International Limited | Skincare compositions |
Non-Patent Citations (2)
| Title |
|---|
| CURRENT DRUG DELIVERY DEC 2010, vol. 7, no. 5, December 2010 (2010-12-01), pages 415 - 420, ISSN: 1875-5704 * |
| DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 2010 (2010-12-01), PADULA CRISTINA ET AL: "Combined patch containing salicylic acid and nicotinamide: role of drug interaction.", XP002723684, Database accession no. NLM20950260 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12440530B2 (en) | 2013-03-01 | 2025-10-14 | Envy Medical, Inc. | Skin solution with solubilized bakuchiol |
| CN106214532A (en) * | 2016-07-26 | 2016-12-14 | 广州智媛生物科技有限公司 | There is compositions of control oil bacteriostasis efficacy and preparation method thereof |
| CN106214532B (en) * | 2016-07-26 | 2019-04-19 | 广州智媛生物科技有限公司 | Composition and preparation method thereof with oil-control bacteriostasis efficacy |
| US11110049B2 (en) | 2017-06-23 | 2021-09-07 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| US10874600B2 (en) | 2018-06-18 | 2020-12-29 | The Procter & Gamble Company | Method for degrading bilirubin in skin |
| US11622963B2 (en) | 2018-07-03 | 2023-04-11 | The Procter & Gamble Company | Method of treating a skin condition |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US11911498B2 (en) | 2020-06-01 | 2024-02-27 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2511350A (en) | 2014-09-03 |
| GB201303640D0 (en) | 2013-04-17 |
| GB2511350B (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11135457B2 (en) | Skincare compositions | |
| WO2014132060A1 (en) | Skincare compositions | |
| EP1722749B1 (en) | Skincare compositions containing salicylic acid | |
| US20070166337A1 (en) | Skincare compositions and methods | |
| US20120207812A1 (en) | Skincare compositions comprising salicyclic acid | |
| WO2014155111A1 (en) | Skincare compositions | |
| WO2008053246A1 (en) | Acne treatment | |
| RU2351310C2 (en) | Compositions for skin care and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14709378 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14709378 Country of ref document: EP Kind code of ref document: A1 |